Michael D Dake1, Fabrizio Fanelli2, Aaron E Lottes3, Erin E O'Leary4, Heidi Reichert5, Xiaohui Jiang5, Weiguo Fu6, Osamu Iida7, Kan Zen8, Marc Schermerhorn9, Thomas Zeller10, Gary M Ansel11. 1. The University of Arizona, Health Sciences Innovation Building, 1670 East Drachman Street, 9th Floor SVP Suite, P.O. Box 210216, Tucson, AZ, 85721-0216, USA. mddake@email.arizona.edu. 2. Department of Vascular and Interventional Radiology, "Careggi" University Hospital, Florence, Italy. 3. Purdue University, West Lafayette, IN, USA. 4. Cook Research Incorporated, West Lafayette, IN, USA. 5. EpidStrategies, Ann Arbor, MI, USA. 6. Department of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China. 7. Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Japan. 8. Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. 9. Division of Vascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA. 10. Universitaets-Herz-Zentrum Freiburg - Bad Krozingen, Bad Krozingen, Germany. 11. Department of Medicine, Ohio Health/Riverside Methodist Hospital, Columbus, OH, USA.
Abstract
PURPOSE: Develop a prediction model to determine the impact of patient and lesion factors on freedom from target lesion revascularization (ffTLR) for patients who are candidates for Zilver PTX drug-eluting stent (DES) treatment for femoropopliteal lesions. METHODS: Patient factors, lesion characteristics, and TLR results from five global studies were utilized for model development. Factors potentially associated with TLR (sex, age, diabetes, hypertension, hypercholesterolemia, renal disease, smoking status, Rutherford classification, lesion length, reference vessel diameter (RVD), popliteal involvement, total occlusion, calcification severity, prior interventions, and number of runoff vessels) were analyzed in a Cox proportional hazards model. Probability of ffTLR was generated for three example patient profiles via combinations of patient and lesion factors. TLR was defined as reintervention performed for ≥ 50% diameter stenosis after recurrent clinical symptoms. RESULTS: The model used records from 2227 patients. The median follow-up time was 23.9 months (range: 0.03-60.8). The Kaplan-Meier estimates for ffTLR were 90.5% through 1 year and 75.2% through 5 years. In a multivariate analysis, sex, age, Rutherford classification, lesion length, RVD, total occlusion, and prior interventions were significant factors. The example patient profiles have predicted 1-year ffTLRs of 97.4, 92.3, and 86.0% and 5-year predicted ffTLRs of 92.8, 79.5, and 64.8%. The prediction model is available as an interactive web-based tool ( https://cooksfa.z13.web.core.windows.net ). CONCLUSIONS: This is the first prediction model that uses an extensive dataset to determine the impact of patient and lesion factors on ffTLR through 5 years and provides an interactive web-based tool for expected patient outcomes with the Zilver PTX DES. CLINICAL TRIAL REGISTRATIONS: Zilver PTX RCT unique identifier: NCT00120406; Zilver PTX single-arm study unique identifier: NCT01094678; Zilver PTX China study unique identifier: NCT02171962; Zilver PTX US post-approval study unique identifier: NCT01901289; Zilver PTX Japan post-market surveillance study unique identifier: NCT02254837. LEVELS OF EVIDENCE: Zilver PTX RCT: Level 2, randomized controlled trial; Single-arm study: Level 4, large case series; China study: Level 4, case series; US post-approval study: Level 4, case series Japan PMS study: Level 4, large case series.
PURPOSE: Develop a prediction model to determine the impact of patient and lesion factors on freedom from target lesion revascularization (ffTLR) for patients who are candidates for Zilver PTX drug-eluting stent (DES) treatment for femoropopliteal lesions. METHODS: Patient factors, lesion characteristics, and TLR results from five global studies were utilized for model development. Factors potentially associated with TLR (sex, age, diabetes, hypertension, hypercholesterolemia, renal disease, smoking status, Rutherford classification, lesion length, reference vessel diameter (RVD), popliteal involvement, total occlusion, calcification severity, prior interventions, and number of runoff vessels) were analyzed in a Cox proportional hazards model. Probability of ffTLR was generated for three example patient profiles via combinations of patient and lesion factors. TLR was defined as reintervention performed for ≥ 50% diameter stenosis after recurrent clinical symptoms. RESULTS: The model used records from 2227 patients. The median follow-up time was 23.9 months (range: 0.03-60.8). The Kaplan-Meier estimates for ffTLR were 90.5% through 1 year and 75.2% through 5 years. In a multivariate analysis, sex, age, Rutherford classification, lesion length, RVD, total occlusion, and prior interventions were significant factors. The example patient profiles have predicted 1-year ffTLRs of 97.4, 92.3, and 86.0% and 5-year predicted ffTLRs of 92.8, 79.5, and 64.8%. The prediction model is available as an interactive web-based tool ( https://cooksfa.z13.web.core.windows.net ). CONCLUSIONS: This is the first prediction model that uses an extensive dataset to determine the impact of patient and lesion factors on ffTLR through 5 years and provides an interactive web-based tool for expected patient outcomes with the Zilver PTX DES. CLINICAL TRIAL REGISTRATIONS: Zilver PTX RCT unique identifier: NCT00120406; Zilver PTX single-arm study unique identifier: NCT01094678; Zilver PTX China study unique identifier: NCT02171962; Zilver PTX US post-approval study unique identifier: NCT01901289; Zilver PTX Japan post-market surveillance study unique identifier: NCT02254837. LEVELS OF EVIDENCE: Zilver PTX RCT: Level 2, randomized controlled trial; Single-arm study: Level 4, large case series; China study: Level 4, case series; US post-approval study: Level 4, case series Japan PMS study: Level 4, large case series.
Authors: Maayan Konigstein; Mahesh V Madhavan; Ori Ben-Yehuda; Hussein M Rahim; Iva Srdanovic; Fotis Gkargkoulas; Ghazaleh Mehdipoor; Evan Shlofmitz; Akiko Maehara; Björn Redfors; Ankita K Gore; Thomas McAndrew; Gregg W Stone; Ziad A Ali Journal: Am Heart J Date: 2019-04-12 Impact factor: 4.749
Authors: Liang Tang; John R Lesser; Mario Gössl; Marcus R Burns; Lynelle M Schneider; Jonathan G Schwartz; Hiroki Niikura; Desmond B Jay; Paul Sorajja Journal: Circ Cardiovasc Interv Date: 2018-09 Impact factor: 6.546
Authors: Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Scott A Snyder; Erin E O'Leary; Gunnar Tepe; Dierk Scheinert; Thomas Zeller Journal: J Am Coll Cardiol Date: 2013-04-10 Impact factor: 24.094
Authors: William A Gray; Koen Keirse; Yoshimitsu Soga; Andrew Benko; Anvar Babaev; Yoshiaki Yokoi; Henrik Schroeder; Jeffery T Prem; Andrew Holden; Jeffrey Popma; Michael R Jaff; Juan Diaz-Cartelle; Stefan Müller-Hülsbeck Journal: Lancet Date: 2018-09-24 Impact factor: 79.321
Authors: Kenneth Rosenfield; Michael R Jaff; Christopher J White; Krishna Rocha-Singh; Carlos Mena-Hurtado; D Christopher Metzger; Marianne Brodmann; Ernst Pilger; Thomas Zeller; Prakash Krishnan; Roger Gammon; Stefan Müller-Hülsbeck; Mark R Nehler; James F Benenati; Dierk Scheinert Journal: N Engl J Med Date: 2015-06-24 Impact factor: 91.245
Authors: Michael D Dake; Dierk Scheinert; Gunnar Tepe; Jörg Tessarek; Fabrizio Fanelli; Marc Bosiers; Christof Ruhlmann; Zaza Kavteladze; Aaron E Lottes; Anthony O Ragheb; Thomas Zeller Journal: J Endovasc Ther Date: 2011-10 Impact factor: 3.487
Authors: Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Thomas Zeller; Gary S Roubin; Mark W Burket; Yazan Khatib; Scott A Snyder; Anthony O Ragheb; J King White; Lindsay S Machan Journal: Circ Cardiovasc Interv Date: 2011-09-27 Impact factor: 6.546
Authors: Gunnar Tepe; John Laird; Peter Schneider; Marianne Brodmann; Prakash Krishnan; Antonio Micari; Christopher Metzger; Dierk Scheinert; Thomas Zeller; David J Cohen; David B Snead; Beaux Alexander; Mario Landini; Michael R Jaff Journal: Circulation Date: 2014-12-03 Impact factor: 29.690
Authors: Michael D Dake; Gary M Ansel; Michael R Jaff; Takao Ohki; Richard R Saxon; H Bob Smouse; Lindsay S Machan; Scott A Snyder; Erin E O'Leary; Anthony O Ragheb; Thomas Zeller Journal: Circulation Date: 2016-03-11 Impact factor: 29.690